PCSK9 and cardiac arrest: PCSK9 inhibitor therapy did not significantly reduce the risk of SCD (RR 0.83, 95% CI 0.54–1.28; P = 0.40; I2 = 0%), ventricular arrhythmias (RR 0.81, 95% CI 0.60–1.09; P = 0.17; I2 = 0%), and cardiac arrest (RR 1.20, 95% CI 0.61–2.33; P = 0.60; I2 = 0%).